Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs.

Big Pharma is accelerating biotech acquisitions to secure innovative drugs, favoring purchases over in-house R&D. Merck’s recent $600M+ deal for Terns Pharmaceuticals highlights this trend, signaling renewed M&A momentum in the sector. Biotech stocks are poised for growth as consolidation rises, driven by large pharmaceutical firms seeking late-stage drug pipelines. Investors benefit from increased deal flow and higher valuations for promising biotech startups. New drug approvals, particularly in oncology and rare diseases, are fueling sector optimism. Regulatory breakthroughs and clinical trial successes are attracting Big Pharma buyers eager to expand portfolios quickly. The biotech M&A resurgence follows a post-pandemic slowdown, with 2026 deals projected to surpass 2025 levels. Analysts cite favorable financing conditions and a backlog of high-potential targets as key drivers. Smaller biotechs with niche therapies or platform technologies remain prime acquisition targets. Strategic buyers prioritize firms with FDA-approved assets or Phase 3 candidates to fast-track revenue growth.